Myasthenia gravis (MG) is a chronic, immune-mediated neuromuscular junction disorder characterized by fluctuating skeletal muscle weakness and fatigability. Clinically, weakness often worsens with use and improves with rest, reflecting impaired signal transmission from motor neurons to muscle fibers. MG is most commonly autoimmune; in many patients, antibodies target components of the postsynaptic neuromuscular junction, disrupting acetylcholine receptor (AChR) function and reducing the number of functional receptor sites.
At the cellular level, normal neuromuscular transmission depends on acetylcholine release, binding to nicotinic AChRs, and generation of an end-plate potential that triggers muscle action potentials. In MG, autoantibodies and complement activation interfere with AChR clustering or function, causing a decreased safety margin for neuromuscular transmission. As fatigue accumulates during repetitive activity, the reduced end-plate potential fails more readily to reach threshold, producing symptom fluctuation across the day and with tasks such as chewing, climbing stairs, or speaking.
MG commonly presents in one of two patterns. Ocular MG involves extraocular muscles and may cause ptosis and diplopia. Generalized MG includes bulbar symptoms (dysarthria, dysphagia), limb weakness, and sometimes respiratory involvement. Severity can vary from mild, localized ocular symptoms to life-threatening respiratory weakness. A key clinical feature is variability: symptoms may fluctuate hour-to-hour, and stress, infections, surgery, or certain medications can exacerbate weakness.
Diagnosis integrates clinical history, neurologic examination, and confirmatory testing. Bedside assessment focuses on fatigable weakness; repetitive nerve stimulation or single-fiber electromyography may demonstrate impaired neuromuscular transmission. Serologic testing detects antibodies such as anti-AChR and anti-muscle-specific kinase (MuSK). Additional antibodies (e.g., LRP4) may be relevant in selected cases. Imaging for thymic abnormalities is standard because thymic hyperplasia and thymoma are associated with MG, and thymic pathology can inform management.
Treatment aims to (1) improve neuromuscular transmission, (2) suppress immune-mediated injury, (3) address associated thymic disease, and (4) manage acute exacerbations. Symptomatic therapy often includes acetylcholinesterase inhibitors such as pyridostigmine, which increase acetylcholine availability in the synaptic cleft and can improve strength. Patients require careful dosing because excessive cholinergic activity can cause muscarinic side effects including diarrhea, abdominal cramps, urinary urgency, and bradycardia.
Disease-modifying therapy is typically immunosuppressive. Corticosteroids can reduce antibody-mediated and complement-mediated damage, though early treatment may transiently worsen weakness in some patients. Steroid-sparing agents (e.g., azathioprine, mycophenolate mofetil, tacrolimus) are used to reduce long-term steroid exposure. For refractory MG or rapid disease control needs, biologic and targeted therapies may be considered. In selected antibody profiles and clinical contexts, IVIG (intravenous immunoglobulin) or plasma exchange can provide faster, temporary improvement by modulating immune activity and removing pathogenic antibodies.
Thymectomy is recommended in many patients with thymoma and is considered for appropriate non-thymoma cases, particularly depending on age, antibody status, and disease course. The rationale is that the thymus can contribute to abnormal immune education, and removal may improve long-term outcomes.
Because MG can unpredictably progress, patient education and safety planning are essential. Respiratory weakness requires urgent evaluation; red flags include shortness of breath at rest, inability to clear secretions, weak cough, or rapid deterioration after triggers. Exacerbations (myasthenic crisis) may require intensive monitoring and ventilatory support. Preventive measures include infection management, minimizing physiologic stress when possible, and individualized avoidance of medications known to worsen MG (selection depends on current guidelines and specific drug classes).
Daily living strategies focus on optimizing energy and minimizing fatigue. Patients often benefit from pacing activities, using scheduled rest periods, and adapting tasks that demand repetitive muscle activation. Speech and swallowing therapy can reduce bulbar symptom complications such as aspiration. Nutritional counseling and swallowing assessment may be needed in those with dysphagia.
Psychological and functional well-being are also important. Chronic, fluctuating weakness can cause anxiety, frustration, and social withdrawal. Clinicians should screen for depression and anxiety, and employ supportive counseling and coping strategies to improve adherence and quality of life. Since symptoms fluctuate, building predictable routines around symptom diaries and medication timing can strengthen self-management.
Finally, treatment is increasingly personalized. Antibody status (AChR, MuSK), thymic findings, comorbidities, and prior response to therapy guide therapeutic selection. Ongoing follow-up with neurology and coordinated care with rehabilitation, speech therapy, and primary care helps reduce complications, identify drug-related issues, and monitor for respiratory risk.
Source: WebMD
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
